Abstract
Background: Interleukin-11 (IL-11) could promote invasion and metastasis of cancer cells, however, its mechanism is unclear.
Objective: This study aimed to investigate the effects of recombinant human IL-11 (rhIL-11) on lung cancer cell metastasis and growth.
Methods: Human lung cancer cell, A549, was cultured and subcutaneously injected into mice to establish Xenograft tumor models. Tumor models were divided into control, rhIL-11 transplantation (250 μg/kg/day), and rhIL-11 transplantation (500 μg/kg/day) group. Tumor volumes were recorded and measured 6 times. Hypoxia- Inducible Factor 1α (HIF1α), snail, slug, Signal Transducers/Activators of Transcription-3 (STAT3), E-cadherin, twist, and vimentin levels were evaluated using western blot and Real-Time PCR (RT-PCR).
Results: Sizes of subcutaneous tumors increased following measurement time. rhIL-11 treatment significantly enhanced HIF1α and STAT3 expression in rhIL-11 treatment groups compared to the control group (p<0.05). However, no remarkable differences were discovered between rhIL-11 (250 μg/kg/day) and rhIL-11 (500 μg/kg/day) group (p>0.05). rhIL-11 treatments significantly increased twist, and slug expressions compared to control group (p<0.05), especially for rhIL-11 (500 μg/kg/day) treatment, which triggered significantly higher effects on twist and slug expressions compared to those in the control group (p<0.05). Vimentin and snail mRNA levels were significantly up-regulated and E-cadherin level was significantly down-regulated in rhIL-11 treatment groups compared to the control group (p<0.05). Meanwhile, rhIL-11 at a dosage of 500 μg/kg/day triggered remarkably higher effects on vimentin, snail, and E-cadherin expressions compared to those in rhIL-11 (250 μg/kg/day) group (p<0.05).
Conclusion: rhIL-11 transplantation promoted growth and Epithelial-Mesenchymal Transition (EMT) of A549 cells, which might be associated with STAT3/HIF-1α/EMT signaling pathway activation.
Keywords: Interleukin-11, epithelial-mesenchymal transition, hypoxia-inducible factor 1α, lung cancer, signaling pathway, STAT3.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Recombinant Human IL-11 Promotes Lung Adenocarcinoma A549 Cell Growth and EMT through Activating STAT3/HIF-1α/EMT Signaling Pathway
Volume: 21 Issue: 15
Author(s): Na Peng, Meijun Lu, Mafei Kang*, Xiuli Liu, Bihui Li and Cuimei Dong
Affiliation:
- Department of Medical Oncology, The Affiliated Hospital of Guilin Medical University, Guilin,China
Keywords: Interleukin-11, epithelial-mesenchymal transition, hypoxia-inducible factor 1α, lung cancer, signaling pathway, STAT3.
Abstract:
Background: Interleukin-11 (IL-11) could promote invasion and metastasis of cancer cells, however, its mechanism is unclear.
Objective: This study aimed to investigate the effects of recombinant human IL-11 (rhIL-11) on lung cancer cell metastasis and growth.
Methods: Human lung cancer cell, A549, was cultured and subcutaneously injected into mice to establish Xenograft tumor models. Tumor models were divided into control, rhIL-11 transplantation (250 μg/kg/day), and rhIL-11 transplantation (500 μg/kg/day) group. Tumor volumes were recorded and measured 6 times. Hypoxia- Inducible Factor 1α (HIF1α), snail, slug, Signal Transducers/Activators of Transcription-3 (STAT3), E-cadherin, twist, and vimentin levels were evaluated using western blot and Real-Time PCR (RT-PCR).
Results: Sizes of subcutaneous tumors increased following measurement time. rhIL-11 treatment significantly enhanced HIF1α and STAT3 expression in rhIL-11 treatment groups compared to the control group (p<0.05). However, no remarkable differences were discovered between rhIL-11 (250 μg/kg/day) and rhIL-11 (500 μg/kg/day) group (p>0.05). rhIL-11 treatments significantly increased twist, and slug expressions compared to control group (p<0.05), especially for rhIL-11 (500 μg/kg/day) treatment, which triggered significantly higher effects on twist and slug expressions compared to those in the control group (p<0.05). Vimentin and snail mRNA levels were significantly up-regulated and E-cadherin level was significantly down-regulated in rhIL-11 treatment groups compared to the control group (p<0.05). Meanwhile, rhIL-11 at a dosage of 500 μg/kg/day triggered remarkably higher effects on vimentin, snail, and E-cadherin expressions compared to those in rhIL-11 (250 μg/kg/day) group (p<0.05).
Conclusion: rhIL-11 transplantation promoted growth and Epithelial-Mesenchymal Transition (EMT) of A549 cells, which might be associated with STAT3/HIF-1α/EMT signaling pathway activation.
Export Options
About this article
Cite this article as:
Peng Na, Lu Meijun , Kang Mafei *, Liu Xiuli , Li Bihui and Dong Cuimei , Recombinant Human IL-11 Promotes Lung Adenocarcinoma A549 Cell Growth and EMT through Activating STAT3/HIF-1α/EMT Signaling Pathway, Anti-Cancer Agents in Medicinal Chemistry 2021; 21 (15) . https://dx.doi.org/10.2174/1871520621666201207091248
DOI https://dx.doi.org/10.2174/1871520621666201207091248 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Evaluation of Potential Cytotoxic Effect of Different Proton Pump Inhibitors on Different Human Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Regulatory T Cell Counts and Development of Malignancy in Patients with HIV Infection
Current HIV Research Structure-Based Virtual Screening for Defeating Drug Resistant Form of EGFR Protein
Combinatorial Chemistry & High Throughput Screening The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?
Current Pharmaceutical Biotechnology ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology Organosulfur Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Natural Compounds Used as Therapies Targeting to Amyotrophic Lateral Sclerosis
Current Pharmaceutical Biotechnology Current Status and Perspectives in Peptide Receptor Radiation Therapy
Current Pharmaceutical Design Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates
Anti-Cancer Agents in Medicinal Chemistry Nanostructural Hybrid Sensitizers for Photodynamic Therapy
Current Pharmaceutical Design Exploring siRNA Umpired Nanogels: A Tale of Barrier Combating Carrier
Current Pharmaceutical Design Potential Utility of Mycobacterium w Vaccine in Control of Tuberculosis
Current Respiratory Medicine Reviews A Comprehensive Review on Oxysterols and Related Diseases
Current Medicinal Chemistry Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
Current Drug Targets Safety of Technosphere Inhaled Insulin
Current Drug Safety Flavonoids on Allergy
Current Pharmaceutical Design Treatment of Pancreatic Cancer with Pharmacological Ascorbate
Current Pharmaceutical Biotechnology Peeking into the Black Box: How Cytokine Antibody Arrays Shed Light on Molecular Mechanisms of Breast Cancer Development and its Treatment
Current Proteomics Immune Checkpoint Inhibitors: Basics and Challenges
Current Medicinal Chemistry The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Current Pharmaceutical Design